We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+15.54%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$855M
AUM Growth
+$208M
Cap. Flow
+$133M
Cap. Flow %
15.53%
Top 10 Hldgs %
33.51%
Holding
104
New
21
Increased
54
Reduced
10
Closed
11

Top Buys

Rank Stock Value
1
COV
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
+$28.3M
2
STJ
St Jude Medical
STJ
+$21.6M
3
TRNX
TORNIER N V SHARES (NLD)
TRNX
+$9.49M
4
SLXP
SALIX PHARMACEUTICALS LTD DEL
SLXP
+$9.39M
5
XLV icon
State Street Health Care Select Sector SPDR ETF
XLV
+$9.37M

Top Sells

Rank Stock Value
1
TMO icon
Thermo Fisher Scientific
TMO
+$13.2M
2
GILD icon
Gilead Sciences
GILD
+$11.2M
3
PCRX icon
Pacira BioSciences
PCRX
+$9.89M
4
ATHN
Athenahealth, Inc.
ATHN
+$8.92M
5
CAH icon
Cardinal Health
CAH
+$6.91M

Sector Composition

Rank Sector Weight
1 Healthcare 73.14%
2 Financials 1.36%
3 Technology 0.94%
4 Industrials 0.77%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DARE icon
76
Dare Bioscience
DARE
$21M
$3.42M 0.4%
4,583
+3,869
+542% +$2.41M
FPRX
77
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$3.24M 0.38%
120,000
+5,000
+4% +$86.1K
RARE icon
78
Ultragenyx Pharmaceutical
RARE
$2.55B
$3.12M 0.36%
71,000
+3,500
+5% +$160K
CSLT
79
DELISTED
CASTLIGHT HEALTH, INC.
CSLT
$3.04M 0.36%
+260,200
New +$3.11M
ICPT
80
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$2.56M 0.3%
16,400
+1,300
+9% +$240K
TRIV
81
DELISTED
TRIVASCULAR TECHONOLOGIES, INC, COMMON STOCK
TRIV
$2.49M 0.29%
+198,000
New +$2.7M
PFNX
82
DELISTED
Pfenex Inc.
PFNX
$2.4M 0.28%
328,100
+3,100
+1% +$23.5K
BLUE
83
DELISTED
bluebird bio
BLUE
$2.29M 0.27%
+1,930
New +$1.29M
XNPT
84
DELISTED
XENOPORT, INC.
XNPT
$2.06M 0.24%
235,000
+89,000
+61% +$654K
KIN
85
DELISTED
Kindred Biosciences, Inc.
KIN
$2.05M 0.24%
275,000
– –
GWPH
86
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$1.9M 0.22%
+28,000
New +$2.05M
ADXS
87
DELISTED
Advaxis Inc
ADXS
$1.8M 0.21%
+15,000
New +$843K
HRTX icon
88
Heron Therapeutics
HRTX
$92.9M
$1.61M 0.19%
160,000
+90,000
+129% +$735K
ETRM
89
DELISTED
EnteroMedics Inc.
ETRM
$1.6M 0.19%
1,071
– –
DERM
90
DELISTED
Dermira, Inc.
DERM
$1.58M 0.18%
+87,274
New +$1.46M
ROKA
91
DELISTED
Sorrento Tech, Inc. Common Stock
ROKA
$1.1M 0.13%
25,000
– –
CBAY
92
DELISTED
Cymabay Therapeutics
CBAY
$983K 0.12%
100,000
-200,000
-67% -$1.61M
BLCM
93
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$806K 0.09%
+3,500
New +$751K
A icon
94
Agilent Technologies
A
$41.2B
– –
-101,355
Closed -$4.13M
ADVM
95
DELISTED
Adverum Biotechnologies
ADVM
– –
-720
Closed -$246K
ARWR icon
96
Arrowhead Research
ARWR
$12.4B
– –
-115,000
Closed -$1.7M
CAH icon
97
Cardinal Health
CAH
$55.4B
– –
-92,250
Closed -$6.91M
INVA icon
98
Innoviva
INVA
$1.48B
– –
-190,000
Closed -$3.25M
PCRX icon
99
Pacira BioSciences
PCRX
$997M
– –
-102,000
Closed -$9.89M
TMO icon
100
Thermo Fisher Scientific
TMO
$220B
– –
-108,500
Closed -$13.2M
1 2 3
4
5

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q4 2014 Portfolio in Review

As of Q4 2014, Rock Springs Capital Management held 104 positions worth $855M, up 32% from $646M the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Rock Springs Capital Management deployed $133M of net new capital in Q4 2014, opening 21 new positions and adding to 54 existing holdings. Its largest new stake was COVIDIEN PLC COM SHS NEW (IRELAND): 295,000 shares worth $30.2M.

By sector, the portfolio is most concentrated in Healthcare at 73% of assets, down from 79% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was Gilead Sciences, an estimated $11.2M trimmed.

  • Rock Springs Capital Management's largest Q4 2014 buy was COVIDIEN PLC COM SHS NEW (IRELAND): 295,000 shares worth $30.2M.
  • Rock Springs Capital Management added most to Acadia Healthcare in Q4 2014, an estimated $7.38M increase.
  • Rock Springs Capital Management's biggest Q4 2014 reduction was Gilead Sciences, cutting an estimated $11.2M.
  • Rock Springs Capital Management fully exited Thermo Fisher Scientific in Q4 2014, selling an estimated $13.2M.
  • Rock Springs Capital Management's ten largest holdings make up 34% of its $855M portfolio in Q4 2014.
  • Rock Springs Capital Management opened 21 new positions and closed 11 in Q4 2014.
  • Rock Springs Capital Management's portfolio value rose 32% quarter-over-quarter to $855M.

Based on Rock Springs Capital Management's 13F filing for Q4 2014, filed 17 Feb 2015.